2,2-dimethyl-3-cyclobutyl propan-3-one | 80875-33-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,2-dimethyl-3-cyclobutyl propan-3-one
• 英文别名: t-butylcyclobutylketone；1-cyclobutyl-2,2-dimethyl-propan-1-one；Trimethylacetyl-cyclobutan；tert.-Butyl-cyclobutyl-keton；1-Cyclobutyl-2,2-dimethyl-propan-1-on；1-Cyclobutyl-2,2-dimethylpropan-1-one
• CAS: 80875-33-8
• 化学式: C₉H₁₆O
• 分子量: 140.225
• InChiKey: OHUBVXYJTFFATH-UHFFFAOYSA-N

物化性质

• 沸点：
  97 °C(Press: 17 Torr)
• 密度：
  0.923±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,2-dimethyl-3-cyclobutyl propan-3-one 在 吡啶 、 草酰氯 、 palladium diacetate 、 N-氟代双苯磺酰胺 作用下， 以 二氯甲烷 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 12.0h， 生成 N-(3,5-bis(trifluoromethyl)phenyl)-2-(((1-cyclobutyl-3-fluoro-2,2-dimethylpropylidene)amino)oxy)acetamide
  参考文献：
  名称：

  Regioselective C(sp³)–H fluorination of ketones: from methyl to the monofluoromethyl group

  摘要：

  通过钯催化的β-选择性甲基C(sp3)-H氟化，开发了一种用于合成含CH2F基团的酮类化合物的新策略。

  DOI：

  10.1039/d0cc07093a
• 作为产物：
  描述：

  频哪酮 在 乙醚 、 sodium amide 作用下， 生成 2,2-dimethyl-3-cyclobutyl propan-3-one
  参考文献：
  名称：

  Billon, Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1922, vol. 174, p. 1709

  摘要：

  DOI：

文献信息

• Hepatitis C Virus Inhibitors
  申请人：Belema Makonen

  公开号：US20100080772A1

  公开（公告）日：2010-04-01

  The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

  本公开涉及化合物、组合物和治疗丙型肝炎病毒（HCV）感染的方法。还公开了含有这些化合物的药物组合物以及使用这些化合物治疗HCV感染的方法。
• SOLUBLE GUANYLATE CYCLASE ACTIVATORS
  申请人：Tan John Q.

  公开号：US20130210798A1

  公开（公告）日：2013-08-15

  This inventions relates to compounds having the structure Formula I and pharmaceutically acceptable salts thereof which are soluble guanylate cyclase activators. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

  这项发明涉及具有结构式I的化合物及其可接受的药用盐，这些化合物是可溶性鸟苷酸环化酶激活剂。这些化合物对于治疗或预防心血管疾病、内皮功能障碍、舒张功能障碍、动脉粥样硬化、高血压、肺动脉高压、心绞痛、血栓形成、再狭窄、心肌梗死、中风、心脏功能不全、肺动脉高压、勃起功能障碍、支气管哮喘、慢性肾功能不全、糖尿病或肝硬化方面是有用的。
• Branched amides of L-aspartyl-D-amino acid dipeptides
  申请人：Pfizer Inc.

  公开号：US04454328A1

  公开（公告）日：1984-06-12

  Amides of L-aspartyl-D-amino acid dipeptides of the formula ##STR1## and physiologically acceptable cationic and acid addition salts thereof wherein R.sup.a is CH.sub.2 OH or CH.sub.2 OCH.sub.3 ; R is a branched member selected from the group consisting of fenchyl, diisopropylcarbinyl, d-methyl-t-butylcarbinyl, d-ethyl-t-butylcarbinyl, di-t-butylcarbinyl, 2-methylthio-2,4-dimethylpentan-3-yl, ##STR2## where at least one of R.sup.3, R.sup.4, R.sup.5, R.sup.6 is alkyl having from one to four carbon atoms and the remainder are hydrogen or alkyl having from one to four carbon atoms, X is O, S, SO, SO.sub.2, C.dbd.O or CHOH; m is zero or 1-4, n and p are each zero, 1, 2 or 3 where the sum of n+p is not greater than 3 and the sum of the carbon atoms in R.sup.3, R.sup.4, R.sup.5 and R.sup.6 is not greater than six, and when both of R.sup.3 and R.sup.4 or R.sup.5 and R.sup.6 are alkyl they are methyl or ethyl, ##STR3## where one of R.sup.7, R.sup.8, R.sup.9 is alkyl having from one to four carbon atoms and the remainder are hydrogen or alkyl having from one to four carbon atoms and the sum of the carbon atoms in R.sup.7, R.sup.8 and R.sup.9 is not greater than six, m and q are the same or different and each have the values previously defined for m; ##STR4## where each of R.sup.12 and R.sup.13 are methyl or ethyl, or R.sup.12 is hydrogen and R.sup.13 is alkyl having from one to four carbon atoms, Z is O or NH and t is 1 or 2, ##STR5## where W is 1-4, R.sup.14 and R.sup.16 are each alkyl having from one to four carbon atoms, R.sup.15 is H, OH, methyl or ethyl and the sum of the carbon atoms in R.sup.14, R.sup.15 and R.sup.16 is not greater than six and when both of R.sup.14 and R.sup.15 are alkyl they are methyl or ethyl, and ##STR6## where R.sup.17 and R.sup.19 are alkyl having from one to four carbon atoms, R.sup.18 and R.sup.20 are H or alkyl having one to two carbon atoms, A is OH and B is H, OH or CH.sub.3 and taken together A and B are ##STR7## where the sum of the carbon atoms in R.sup.17, R.sup.18, R.sup.19 and R.sup.20 is not greater than six and when both of R.sup.17 and R.sup.18 or R.sup.19 and R.sup.20 are alkyl they are methyl or ethyl; said amides are potent sweeteners having advantages over the prior art, edible compositions containing them, methods for their use in edible compositions and novel amide intermediates useful in their production.

  L-天冬氨酸-D-氨基酸二肽的酰胺，其化学式为##STR1##及其生理上可接受的阳离子和酸盐，其中R.sup.a为CH.sub.2 OH或CH.sub.2 OCH.sub.3；R为从茴香基、二异丙基甲基、d-甲基-t-叔丁基甲基、d-乙基-t-叔丁基甲基、二-t-叔丁基甲基、2-甲硫基-2,4-二甲基戊烷-3-基，##STR2##中选择的支链成员，其中R.sup.3、R.sup.4、R.sup.5、R.sup.6中至少有一个是具有一到四个碳原子的烷基，其余为氢或具有一到四个碳原子的烷基，X为O、S、SO、SO.sub.2、C.dbd.O或CHOH；m为零或1-4，n和p分别为零、1、2或3，其中n+p的总和不大于3，R.sup.3、R.sup.4、R.sup.5和R.sup.6中的碳原子总和不大于六，当R.sup.3和R.sup.4或R.sup.5和R.sup.6中的两个均为烷基时，它们为甲基或乙基，##STR3##其中R.sup.7、R.sup.8、R.sup.9中的一个是具有一到四个碳原子的烷基，其余为氢或具有一到四个碳原子的烷基，R.sup.7、R.sup.8和R.sup.9中的碳原子总和不大于六，m和q相同或不同，且具有先前定义的m的值；##STR4##其中R.sup.12和R.sup.13中的每一个均为甲基或乙基，或R.sup.12为氢且R.sup.13为具有一到四个碳原子的烷基，Z为O或NH，t为1或2，##STR5##其中W为1-4，R.sup.14和R.sup.16均为具有一到四个碳原子的烷基，R.sup.15为H、OH、甲基或乙基，R.sup.14、R.sup.15和R.sup.16中的碳原子总和不大于六，当R.sup.14和R.sup.15均为烷基时，它们为甲基或乙基，以及##STR6##其中R.sup.17和R.sup.19为具有一到四个碳原子的烷基，R.sup.18和R.sup.20为H或具有一到二个碳原子的烷基，A为OH，B为H、OH或CH.sub.3，A和B一起为##STR7##其中R.sup.17、R.sup.18、R.sup.19和R.sup.20中的碳原子总和不大于六，当R.sup.17和R.sup.18或R.sup.19和R.sup.20中的两个均为烷基时，它们为甲基或乙基；所述酰胺是具有优于先前技术的优点的强甜味剂，包含它们的可食用组合物，其在可食用组合物中的使用方法以及在其生产中有用的新型酰胺中间体。
• Substituted Azaspiro(4.5)Decane Derivatives
  申请人：Gruenenthal GmbH

  公开号：US20160016903A1

  公开（公告）日：2016-01-21

  The invention relates to substituted spirocyclic cyclohexane derivatives which have an affinity for the μ opioid receptor and the ORL1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.

  这项发明涉及对取代的螺环烷环己烷衍生物，其具有对μ阿片受体和ORL1受体的亲和力，以及其制备方法、含有这些化合物的药物和利用这些化合物制备药物的用途。
• Triazolyl ethanol derivatives as plant growth regulators
  申请人：Imperial Chemical Industries PLC

  公开号：US04923502A1

  公开（公告）日：1990-05-08

  Triazolyl alcohol derivatives active as plant growth regulating have the general formula: ##STR1## wherein R.sup.1 is a cycloalkyl or cycloalkenyl group containing from 3 to 8 ring carbon atoms and optionally substituted, for example by lower alkyl or halogen; n is 0 or 1 or 3; R.sup.2 is hydrogen or lower alkyl; and R.sup.3 is a tertiary butyl group optionally substituted by one or more halogen atoms. Triazol-1-yl derivatives are preferred.

  三唑醇衍生物作为植物生长调节剂具有以下一般式：##STR1## 其中R.sup.1是含有3到8个环状碳原子的环烷基或环烯基基团，可选择地被较低烷基或卤素取代，n为0或1或3；R.sup.2为氢或较低烷基；R.sup.3是由一个或多个卤素原子取代的三丁基基团。首选三唑-1-基衍生物。